Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
  • Resources
    • 2022 MA Life Sciences Workforce Analysis Report
    • 2021 Massachusetts Biopharma Funding Report
    • 2021 Industry Snapshot
    • 2021 State of Diversity, Equity, & Inclusion Report
    • Economic Development
    • Value of Health
    • Biopharma Startup Toolkit
    • Career Center
    • MassBioEd
  • Events
    • Events Calendar
    • Overview of Events
    • Get Involved
  • Membership
    • Member Directory
    • Benefits of Membership
    • Savings and Rewards
    • Member News
    • Become a Member
    • Member Rates
    • Pay Company Dues
  • Savings & Rewards
    • MassBioEdge
  • Conference Center
    • MassBioHub
  • Programs
    • State of Possible 2025 Report
    • Diversity, Equity, and Inclusion
    • Policy & Advocacy
    • Partnering Week 2022
    • Partnering Opportunities
    • MassBioDrive
    • Digital Health
    • BioReady Communities
  • About Us
    • About Us
    • News & Thought Leadership
    • Sponsorship Opportunities
    • Staff
    • Board of Directors
    • FAQs
    • Contact Us
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
Open search form

Member Directory

Click to Open Main Menu

Syndax Pharmaceuticals

Life Sciences | Drug Development
Waltham, MA 781-419-1400 Website

Overview

We are a late-stage biopharmaceutical company focused on the development and commercialization of our lead product candidate, entinostat, an epigenetic therapy for treatment-resistant cancers. Entinostat was recently granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) based on data from our completed randomized Phase 2b clinical trial in estrogen receptor positive locally recurrent or metastatic breast cancer. This trial showed statistically significant improvement in the primary endpoint of progression-free survival and showed statistically significant improvement in overall survival, an exploratory endpoint. We and our collaborators at the National Cancer Institute (NCI) will evaluate entinostat in a pivotal Phase 3 clinical trial in hormone receptor positive locally advanced or metastatic breast cancer, which we refer to as advanced breast cancer. The Phase 3 clinical trial will be conducted by the ECOG-ACRIN Cancer Research Group under sponsorship and funding support from the NCI. We are supporting the Phase 3 clinical trial under a Cooperative Research and Development Agreement with the NCI and a separate agreement with the ECOG-ACRIN Cancer Research Group. The protocol for the Phase 3 clinical trial was reviewed and agreed upon by the FDA under a Special Protocol Assessment agreement with the NCI in January 2014. The ECOG-ACRIN Cancer Research Group activated the trial in March 2014 and we expect patient enrollment to begin in April 2014.

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • Contact
  • Privacy Policy
  • Fulfillment Policy
  • © 2022 All Rights Reserved